Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia"

Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):1-3. doi: 10.1080/14737167.2022.1986006. Epub 2021 Oct 4.

Authors

Juan M Reyes¹, Jorge LaRotta², Natalia Castano¹, Mark A Fletcher³, Matthew Wasserman⁴, Johnna Perdrizet⁴, Rodrigo Sini de Almeida⁵

Affiliations

¹ Health Economics and Ouctomes Research, Pfizer SAS, Bogotá, Colombia.
² Vaccine Medical, Pfizer SAS, Bogota, Colombia.
³ Vaccine Medical and Scientific affairs, Pfizer Inc, Paris, France.
⁴ Outcome Research, Pfizer Inc, New York, NY, USA.
⁵ Vaccine Medical and Scientific affairs, Pfizer Inc, Sao Paulo, Brazil.

PMID: 34569403
DOI: 10.1080/14737167.2022.1986006

No abstract available

Keywords: Budget impact analysis; colombia; economic analysis; pneumococcal conjugate vaccination; serotypes;Pneumococcal diseases.

Publication types

Comment

MeSH terms

Budgets
Colombia
Humans
Pneumococcal Infections* / epidemiology
Pneumococcal Infections* / prevention & control
Pneumococcal Vaccines*
Vaccines, Conjugate

Substances

Pneumococcal Vaccines
Vaccines, Conjugate